Astellas/Pfizer’s COX-2 Inhibitor Celecox Gains Additional Indications In Japan
This article was originally published in PharmAsia News
Executive Summary
Astellas Pharma and Pfizer Japan June 17 announced additional indications for their COX-2 inhibitor Celecox (celecoxib) in Japan for lumbago, scapulohumeral periarthritis, cervico-omo-brachial syndrome and tendinitis/tendosynovitis